CDER photosafety guidance for industry
Related Experiment Video
Updated: Aug 21, 2026

Minimal Erythema Dose (MED) Testing
Published on: May 28, 2013
Abigail C Jacobs1, Paul C Brown, Conrad Chen
1Center for Drug Evaluation and Research/U.S. Food and Drug Administration, Rockville, Maryland 20857, USA. jacobsa@cder.fda.gov
Abstract:
In the Federal Register of January 10, 2000 (65 FR 1399), FDA published a draft guidance entitled "Photosafety Testing." The notice gave interested persons an opportunity to submit comments. As a result of the comments, certain sections of the guidance were reworded to improve clarity. A final guidance was published in May 2003. The final guidance further emphasizes that a flexible approach can be used to address adverse photoeffects and that specific assays are not required. Moreover, it encourages the development of methods that can efficiently be used to evaluate human safety. The guidance describes a consistent, science-based approach for testing of topically and systemically administered drug products.
More Related Videos
06:31Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response
Published on: October 3, 2019
08:40Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016